The K-ras mutation G12C has recently been exploited to design small molecule inhibitors that show promise for NSCLC treatment.37 However, as illustrated here, mutations in K-ras in pancreatic cancer are predominantly G12V and G12D; there was only a single subject with a G12C K-ras mutation in our study. This evidence concerns the gene KRAS and pancreatic neoplasm.